<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37985854</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2042-0226</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Cellular &amp; molecular immunology</Title><ISOAbbreviation>Cell Mol Immunol</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 and innate immunity: the good, the bad, and the "goldilocks".</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>183</EndPage><MedlinePgn>171-183</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41423-023-01104-y</ELocationID><Abstract><AbstractText>An ancient conflict between hosts and pathogens has driven the innate and adaptive arms of immunity. Knowledge about this interplay can not only help us identify biological mechanisms but also reveal pathogen vulnerabilities that can be leveraged therapeutically. The humoral response to SARS-CoV-2 infection has been the focus of intense research, and the role of the innate immune system has received significantly less attention. Here, we review current knowledge of the innate immune response to SARS-CoV-2 infection and the various means SARS-CoV-2 employs to evade innate defense systems. We also consider the role of innate immunity in SARS-CoV-2 vaccines and in the phenomenon of long COVID.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sievers</LastName><ForeName>Benjamin L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0002-9681-9082</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Mark T K</ForeName><Initials>MTK</Initials><Identifier Source="ORCID">0000-0003-4323-5574</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Csiba</LastName><ForeName>Kata</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge, UK. bm432@cam.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK. bm432@cam.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Ravindra K</ForeName><Initials>RK</Initials><Identifier Source="ORCID">0000-0001-9751-1808</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology &amp; Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Cell Mol Immunol</MedlineTA><NlmUniqueID>101242872</NlmUniqueID><ISSNLinking>1672-7681</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral targets</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Innate immune response</Keyword><Keyword MajorTopicYN="N">Interferon</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>21</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37985854</ArticleId><ArticleId IdType="pmc">PMC10805730</ArticleId><ArticleId IdType="doi">10.1038/s41423-023-01104-y</ArticleId><ArticleId IdType="pii">10.1038/s41423-023-01104-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270&#x2013;3. doi: 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WJ, Liu P, Lei W, Jia Z, He X, Shi W, et al. Surveillance of SARS-CoV-2 at the Huanan Seafood Market. Nature. 2023:1&#x2013;3. 10.1038/s41586-023-06043-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">37019149</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265&#x2013;9. doi: 10.1038/s41586-020-2008-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Edridge AWD, Kaczorowska J, Hoste A, Bakker M, Klein M, Loens K, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med. 2020;26:1691&#x2013;3. doi: 10.1038/s41591-020-1083-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1083-1</ArticleId><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Dijkman R, Jebbink MF, Gaunt E, Rossen JW, Templeton KE, Kuijpers TW, et al. The dominance of human coronavirus OC43 and NL63 infections in infants. J Clin Virol. 2012;53:135&#x2013;9. doi: 10.1016/j.jcv.2011.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.11.011</ArticleId><ArticleId IdType="pmc">PMC7108278</ArticleId><ArticleId IdType="pubmed">22188723</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell. 2021;184:1858&#x2013;64.e10. doi: 10.1016/j.cell.2021.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.010</ArticleId><ArticleId IdType="pmc">PMC7871851</ArticleId><ArticleId IdType="pubmed">33631096</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Lond Engl. 2020;395:565&#x2013;74. doi: 10.1016/S0140-6736(20)30251-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30251-8</ArticleId><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181:914&#x2013;21.e10. doi: 10.1016/j.cell.2020.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.011</ArticleId><ArticleId IdType="pmc">PMC7179501</ArticleId><ArticleId IdType="pubmed">32330414</ArticleId></ArticleIdList></Reference><Reference><Citation>Arya R, Kumari S, Pandey B, Mistry H, Bihani SC, Das A, et al. Structural insights into SARS-CoV-2 proteins. J Mol Biol. 2021;433:166725. doi: 10.1016/j.jmb.2020.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2020.11.024</ArticleId><ArticleId IdType="pmc">PMC7685130</ArticleId><ArticleId IdType="pubmed">33245961</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen NT, Chinn J, Nahmias J, Yuen S, Kirby KA, Hohmann S, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open. 2021;4:e210417. doi: 10.1001/jamanetworkopen.2021.0417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0417</ArticleId><ArticleId IdType="pmc">PMC8547263</ArticleId><ArticleId IdType="pubmed">33666657</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjendra Y, Al Mana AF, Espejo AP, Akgun Y, Millan NC, Gomez-Fernandez C, et al. Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers. Arch Pathol Lab Med. 2020;144:1465&#x2013;74. doi: 10.5858/arpa.2020-0471-SA.</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2020-0471-SA</ArticleId><ArticleId IdType="pubmed">32818235</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476&#x2013;88.e11. doi: 10.1016/j.cell.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L, Mescia F, Turner L, Hanson AL, Kotagiri P, Dunmore BJ, et al. Longitudinal analysis reveals that delayed bystander CD8&#x2009;+&#x2009;T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54:1257&#x2013;75.e8. doi: 10.1016/j.immuni.2021.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473&#x2013;4. doi: 10.1126/science.abb8925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8925</ArticleId><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan C, Li C, Ma H, Li Y, Zhang H. Immunopathogenesis of coronavirus-induced acute respiratory distress syndrome (ARDS): potential infection-associated hemophagocytic lymphohistiocytosis. Clin Microbiol Rev. 2020;34:e00074&#x2013;20. doi: 10.1128/CMR.00074-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00074-20</ArticleId><ArticleId IdType="pmc">PMC7566897</ArticleId><ArticleId IdType="pubmed">33055229</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J-M, An J. Cytokines, inflammation and pain. Int Anesthesiol Clin. 2007;45:27&#x2013;37. doi: 10.1097/AIA.0b013e318034194e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AIA.0b013e318034194e</ArticleId><ArticleId IdType="pmc">PMC2785020</ArticleId><ArticleId IdType="pubmed">17426506</ArticleId></ArticleIdList></Reference><Reference><Citation>Riera Romo M, P&#xe9;rez&#x2010;Mart&#xed;nez D, Castillo Ferrer C. Innate immunity in vertebrates: an overview. Immunology. 2016;148:125&#x2013;39. doi: 10.1111/imm.12597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12597</ArticleId><ArticleId IdType="pmc">PMC4863567</ArticleId><ArticleId IdType="pubmed">26878338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann H-H, Schneider WM, Rice CM. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 2015;36:124&#x2013;38. doi: 10.1016/j.it.2015.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2015.01.004</ArticleId><ArticleId IdType="pmc">PMC4384471</ArticleId><ArticleId IdType="pubmed">25704559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotenko SV, Durbin JE. Contribution of type III interferons to antiviral immunity: location, location, location. J Biol Chem. 2017;292:7295&#x2013;303. doi: 10.1074/jbc.R117.777102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R117.777102</ArticleId><ArticleId IdType="pmc">PMC5418032</ArticleId><ArticleId IdType="pubmed">28289095</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy DE, Mari&#xe9; IJ, Durbin JE. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol. 2011;1:476&#x2013;86. doi: 10.1016/j.coviro.2011.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2011.11.001</ArticleId><ArticleId IdType="pmc">PMC3272644</ArticleId><ArticleId IdType="pubmed">22323926</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355&#x2013;62. doi: 10.1038/s41577-020-0331-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0331-4</ArticleId><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R, Perlman S. Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. J Clin Invest. 2020;130:6204&#x2013;13. doi: 10.1172/JCI144115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI144115</ArticleId><ArticleId IdType="pmc">PMC7685716</ArticleId><ArticleId IdType="pubmed">33085654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasuga Y, Zhu B, Jang K-J, Yoo J-S. Innate immune sensing of coronavirus and viral evasion strategies. Exp Mol Med. 2021;53:723&#x2013;36. doi: 10.1038/s12276-021-00602-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00602-1</ArticleId><ArticleId IdType="pmc">PMC8099713</ArticleId><ArticleId IdType="pubmed">33953325</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Lyu Y, Hou F. SARS-CoV-2 infection and the antiviral innate immune response. J Mol Cell Biol. 2020;12:963&#x2013;7. doi: 10.1093/jmcb/mjaa071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjaa071</ArticleId><ArticleId IdType="pmc">PMC7798998</ArticleId><ArticleId IdType="pubmed">33377937</ArticleId></ArticleIdList></Reference><Reference><Citation>Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783&#x2013;801. doi: 10.1016/j.cell.2006.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.02.015</ArticleId><ArticleId IdType="pubmed">16497588</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;35:266&#x2013;71. doi: 10.1007/s12250-020-00207-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00207-4</ArticleId><ArticleId IdType="pmc">PMC7090474</ArticleId><ArticleId IdType="pubmed">32125642</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasrija R, Naime M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. Int Immunopharmacol. 2021;90:107225. doi: 10.1016/j.intimp.2020.107225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107225</ArticleId><ArticleId IdType="pmc">PMC7691139</ArticleId><ArticleId IdType="pubmed">33302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Streicher F, Jouvenet N. Stimulation of innate immunity by host and viral RNAs. Trends Immunol. 2019;40:1134&#x2013;48. doi: 10.1016/j.it.2019.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2019.10.009</ArticleId><ArticleId IdType="pubmed">31735513</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins JW. Interferon-stimulated genes: what do they all do? Annu Rev Virol. 2019;6:567&#x2013;84. doi: 10.1146/annurev-virology-092818-015756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-092818-015756</ArticleId><ArticleId IdType="pubmed">31283436</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. 2015;15:231&#x2013;42. doi: 10.1038/nri3806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3806</ArticleId><ArticleId IdType="pubmed">25790790</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, et al. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. J Virol. 2020;94. 10.1128/jvi.01410-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654262</ArticleId><ArticleId IdType="pubmed">32938761</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Kanneganti T-D. Innate immunity: the first line of defense against SARS-CoV-2. Nat Immunol. 2022;23:165&#x2013;76. doi: 10.1038/s41590-021-01091-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01091-0</ArticleId><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>Santer DM, Li D, Ghosheh Y, Zahoor MA, Prajapati D, Hansen BE, et al. Interferon-&#x3bb; treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. Nat Commun. 2022;13:6992. doi: 10.1038/s41467-022-34709-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34709-4</ArticleId><ArticleId IdType="pmc">PMC9667439</ArticleId><ArticleId IdType="pubmed">36385011</ArticleId></ArticleIdList></Reference><Reference><Citation>Portela Sousa C, Brites C. Immune response in SARS-CoV-2 infection: the role of interferons type I and type III. Braz J Infect Dis. 2020;24:428&#x2013;33. doi: 10.1016/j.bjid.2020.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjid.2020.07.011</ArticleId><ArticleId IdType="pmc">PMC7448817</ArticleId><ArticleId IdType="pubmed">32866437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14:36&#x2013;49. doi: 10.1038/nri3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3581</ArticleId><ArticleId IdType="pmc">PMC4084561</ArticleId><ArticleId IdType="pubmed">24362405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718&#x2013;24. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20:397&#x2013;8. doi: 10.1038/s41577-020-0346-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0346-x</ArticleId><ArticleId IdType="pmc">PMC7249038</ArticleId><ArticleId IdType="pubmed">32457522</ArticleId></ArticleIdList></Reference><Reference><Citation>Broggi A, Ghosh S, Sposito B, Spreafico R, Balzarini F, Lo Cascio A, et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science. 2020;369:706&#x2013;12. doi: 10.1126/science.abc3545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc3545</ArticleId><ArticleId IdType="pmc">PMC7292499</ArticleId><ArticleId IdType="pubmed">32527925</ArticleId></ArticleIdList></Reference><Reference><Citation>Major J, Crotta S, Llorian M, McCabe TM, Gad HH, Priestnall SL, et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science. 2020;369:712&#x2013;7. doi: 10.1126/science.abc2061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc2061</ArticleId><ArticleId IdType="pmc">PMC7292500</ArticleId><ArticleId IdType="pubmed">32527928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Mehta AK, Patterson TF, Erdmann N, Gomez CA, Jain MK, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:1365&#x2013;76. doi: 10.1016/S2213-2600(21)00384-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00384-2</ArticleId><ArticleId IdType="pmc">PMC8523116</ArticleId><ArticleId IdType="pubmed">34672949</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir&#x2013;ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695&#x2013;704. doi: 10.1016/S0140-6736(20)31042-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31042-4</ArticleId><ArticleId IdType="pmc">PMC7211500</ArticleId><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11:3810. doi: 10.1038/s41467-020-17665-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17665-9</ArticleId><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021;13:eabh2624. doi: 10.1126/scitranslmed.abh2624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abh2624</ArticleId><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570. doi: 10.1126/science.abd4570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkoff JM, tenOever, B. Innate immune evasion strategies of SARS-CoV-2. Nat Rev Microbiol. 2023;21:178&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9838430</ArticleId><ArticleId IdType="pubmed">36631691</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorne LG, Bouhaddou M, Reuschl AK, Zuliani-Alvarez L, Polacco B, Pelin A, et al. Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature. 2022;602:487&#x2013;95. doi: 10.1038/s41586-021-04352-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04352-y</ArticleId><ArticleId IdType="pmc">PMC8850198</ArticleId><ArticleId IdType="pubmed">34942634</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayn M, Hirschenberger M, Koepke L, Nchioua R, Straub JH, Klute S, et al. Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities. Cell Rep. 2021;35:109126. doi: 10.1016/j.celrep.2021.109126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109126</ArticleId><ArticleId IdType="pmc">PMC8078906</ArticleId><ArticleId IdType="pubmed">33974846</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong L-YR, Perlman S. Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses&#x2014;are we our own worst enemy? Nat Rev Immunol. 2022;22:47&#x2013;56. doi: 10.1038/s41577-021-00656-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00656-2</ArticleId><ArticleId IdType="pmc">PMC8617551</ArticleId><ArticleId IdType="pubmed">34837062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Shin E-C. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020;20:585&#x2013;6. doi: 10.1038/s41577-020-00429-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00429-3</ArticleId><ArticleId IdType="pmc">PMC8824445</ArticleId><ArticleId IdType="pubmed">32788708</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanneganti T-D. Intracellular innate immune receptors: Life inside the cell. Immunol Rev. 2020;297:5&#x2013;12. doi: 10.1111/imr.12912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12912</ArticleId><ArticleId IdType="pmc">PMC7592123</ArticleId><ArticleId IdType="pubmed">32856334</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A. A virological view of innate immune recognition. Annu Rev Microbiol. 2012;66:177&#x2013;96. doi: 10.1146/annurev-micro-092611-150203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-micro-092611-150203</ArticleId><ArticleId IdType="pmc">PMC3549330</ArticleId><ArticleId IdType="pubmed">22994491</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20:537&#x2013;51. doi: 10.1038/s41577-020-0288-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0288-3</ArticleId><ArticleId IdType="pmc">PMC7094958</ArticleId><ArticleId IdType="pubmed">32203325</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T, Kato H, Kumagai Y, Yoneyama M, Sato S, Matsushita K, et al. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc Natl Acad Sci USA. 2010;107:1512&#x2013;7. doi: 10.1073/pnas.0912986107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0912986107</ArticleId><ArticleId IdType="pmc">PMC2824407</ArticleId><ArticleId IdType="pubmed">20080593</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahasi K, Kumeta H, Tsuduki N, Narita R, Shigemoto T, Hirai R, et al. Solution structures of cytosolic RNA sensor MDA5 and LGP2 C-terminal domains. J Biol Chem. 2009;284:17465&#x2013;74. doi: 10.1074/jbc.M109.007179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.007179</ArticleId><ArticleId IdType="pmc">PMC2719387</ArticleId><ArticleId IdType="pubmed">19380577</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornbrough JM, Jha BK, Yount B, Goldstein SA, Li Y, Elliott R, et al. Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNase L activation. mBio. 2016;7:e00258. doi: 10.1128/mBio.00258-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00258-16</ArticleId><ArticleId IdType="pmc">PMC4817253</ArticleId><ArticleId IdType="pubmed">27025250</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickenhagen A, Sugrue E, Lytras S, Kuchi S, Noerenberg M, Turnbull ML, et al. A prenylated dsRNA sensor protects against severe COVID-19. Science. 2021;374:eabj3624. doi: 10.1126/science.abj3624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj3624</ArticleId><ArticleId IdType="pmc">PMC7612834</ArticleId><ArticleId IdType="pubmed">34581622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D, Le Pen J, Yatim A, Dong B, Aquino Y, Ogishi M, et al. Inborn errors of OAS&#x2013;RNase L in SARS-CoV-2&#x2013;related multisystem inflammatory syndrome in children. Science. 2022;379:eabo3627. doi: 10.1126/science.abo3627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abo3627</ArticleId><ArticleId IdType="pmc">PMC10451000</ArticleId><ArticleId IdType="pubmed">36538032</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Matuozzo D, Le Pen J, Lee D, Moens L, Asano T, et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J Exp Med. 2022;219:e20220131. doi: 10.1084/jem.20220131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220131</ArticleId><ArticleId IdType="pmc">PMC9206114</ArticleId><ArticleId IdType="pubmed">35708626</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Farzan M. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol. 2013;13:46&#x2013;57. doi: 10.1038/nri3344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3344</ArticleId><ArticleId IdType="pmc">PMC3773942</ArticleId><ArticleId IdType="pubmed">23237964</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CC, Zhong G, Huang I-C, Farzan M. IFITM-family proteins: the cell&#x2019;s first line of antiviral defense. Annu Rev Virol. 2014;1:261&#x2013;83. doi: 10.1146/annurev-virology-031413-085537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-031413-085537</ArticleId><ArticleId IdType="pmc">PMC4295558</ArticleId><ArticleId IdType="pubmed">25599080</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster TL, Pickering S, Neil SJD. Inhibiting the Ins and Outs of HIV replication: cell-intrinsic antiretroviral restrictions at the plasma membrane. Front Immunol. 2018;8:1853. doi: 10.3389/fimmu.2017.01853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01853</ArticleId><ArticleId IdType="pmc">PMC5758531</ArticleId><ArticleId IdType="pubmed">29354117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Li J, Winkler CA, An P, Guo J-T. IFITM genes, variants, and their roles in the control and pathogenesis of viral infections. Front Microbiol. 2019;9:3228. doi: 10.3389/fmicb.2018.03228.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.03228</ArticleId><ArticleId IdType="pmc">PMC6338058</ArticleId><ArticleId IdType="pubmed">30687247</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchrieser J, Dufloo J, Hubert M, Monel B, Planas D, Rajah MM, et al. Syncytia formation by SARS-CoV-2-infected cells. EMBO J. 2021;40:e107405. doi: 10.15252/embj.2020107405.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020107405</ArticleId><ArticleId IdType="pmc">PMC7849166</ArticleId><ArticleId IdType="pubmed">33522642</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster TL, Wilson H, Iyer SS, Coss K, Doores K, Smith S, et al. Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe. 2016;20:429&#x2013;42. doi: 10.1016/j.chom.2016.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.08.006</ArticleId><ArticleId IdType="pmc">PMC5075283</ArticleId><ArticleId IdType="pubmed">27640936</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi G, Schwartz O, Compton AA. More than meets the I: the diverse antiviral and cellular functions of interferon-induced transmembrane proteins. Retrovirology. 2017;14:53. doi: 10.1186/s12977-017-0377-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12977-017-0377-y</ArticleId><ArticleId IdType="pmc">PMC5697417</ArticleId><ArticleId IdType="pubmed">29162141</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudhasani R, Tran JP, Retterer C, Radoshitzky SR, Kota KP, Altamura LA, et al. IFITM-2 and IFITM-3 but Not IFITM-1 restrict Rift Valley fever virus. J Virol. 2013;87:8451&#x2013;64. doi: 10.1128/JVI.03382-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03382-12</ArticleId><ArticleId IdType="pmc">PMC3719792</ArticleId><ArticleId IdType="pubmed">23720721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Sehgal M, Hou Z, Cheng J, Shu S, Wu S, et al. Identification of residues controlling restriction versus enhancing activities of IFITM proteins on entry of human coronaviruses. J Virol. 2018;92:e01535&#x2013;17. doi: 10.1128/JVI.01535-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01535-17</ArticleId><ArticleId IdType="pmc">PMC5827390</ArticleId><ArticleId IdType="pubmed">29263263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Guo F, Liu F, Cuconati A, Chang J, Block TM, et al. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci USA. 2014;111:6756&#x2013;61. doi: 10.1073/pnas.1320856111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1320856111</ArticleId><ArticleId IdType="pmc">PMC4020042</ArticleId><ArticleId IdType="pubmed">24753610</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang R, Case JB, Yutuc E, Ma X, Shen S, Gomez Castro MF, et al. Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. Proc Natl Acad Sci USA. 2020;117:32105&#x2013;13. doi: 10.1073/pnas.2012197117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2012197117</ArticleId><ArticleId IdType="pmc">PMC7749331</ArticleId><ArticleId IdType="pubmed">33239446</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi G, Kenney AD, Kudryashova E, Zani A, Zhang L, Lai KK, et al. Opposing activities of IFITM proteins in SARS-CoV-2 infection. EMBO J. 2021;40:e106501. doi: 10.15252/embj.2020106501.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106501</ArticleId><ArticleId IdType="pmc">PMC7744865</ArticleId><ArticleId IdType="pubmed">33270927</ArticleId></ArticleIdList></Reference><Reference><Citation>Winstone H, Lista MJ, Reid AC, Bouton C, Pickering S, Galao RP, et al. The polybasic cleavage site in SARS-CoV-2 spike modulates viral sensitivity to type I interferon and IFITM2. J Virol. 2021;95:e02422&#x2013;20. doi: 10.1128/JVI.02422-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02422-20</ArticleId><ArticleId IdType="pmc">PMC8104117</ArticleId><ArticleId IdType="pubmed">33563656</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, Abdullahi A, Ferreira I, Goonawardane N, Saito A, Kimura I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706&#x2013;14. doi: 10.1038/s41586-022-04474-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;80.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci. 2009;106:5871&#x2013;6. doi: 10.1073/pnas.0809524106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0809524106</ArticleId><ArticleId IdType="pmc">PMC2660061</ArticleId><ArticleId IdType="pubmed">19321428</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J-E, Li K, Barlan A, Fehr AR, Perlman S, McCray PB JR, et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci. 2016;113:12262&#x2013;7. doi: 10.1073/pnas.1608147113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1608147113</ArticleId><ArticleId IdType="pmc">PMC5086990</ArticleId><ArticleId IdType="pubmed">27791014</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou T, Mou H, Zhang L, Ojha A, Choe H, Farzan M. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. PLOS Pathog. 2021;17:e1009212. doi: 10.1371/journal.ppat.1009212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009212</ArticleId><ArticleId IdType="pmc">PMC7845965</ArticleId><ArticleId IdType="pubmed">33465165</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing E, Li P, Cooper L, Schulz S, J&#xe4;ck HM, Rong L, et al. Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry. Cell Rep. 2022;39:110786. doi: 10.1016/j.celrep.2022.110786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110786</ArticleId><ArticleId IdType="pmc">PMC9015963</ArticleId><ArticleId IdType="pubmed">35477024</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, Datir R, Choi J, CITIID-NIHR Bioresource COVID- C, Bradley JR, Smith K, et al. SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity. Cell Rep. 2022;40:111220. doi: 10.1016/j.celrep.2022.111220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111220</ArticleId><ArticleId IdType="pmc">PMC9346021</ArticleId><ArticleId IdType="pubmed">35963244</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock TP, Goldhill DH, Zhou J, Baillon L, Frise R, Swann OC, et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat Microbiol. 2021;6:899&#x2013;909. doi: 10.1038/s41564-021-00908-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00908-w</ArticleId><ArticleId IdType="pubmed">33907312</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA. 2020;117:7001&#x2013;3. doi: 10.1073/pnas.2002589117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2002589117</ArticleId><ArticleId IdType="pmc">PMC7132130</ArticleId><ArticleId IdType="pubmed">32165541</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung C, Kmiec D, Koepke L, Zech F, Jacob T, Sparrer K, et al. Omicron: what makes the latest SARS-CoV-2 variant of concern so concerning? J Virol. 2022;96:e02077&#x2013;21. doi: 10.1128/jvi.02077-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02077-21</ArticleId><ArticleId IdType="pmc">PMC8941872</ArticleId><ArticleId IdType="pubmed">35225672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022;11:277&#x2013;83. doi: 10.1080/22221751.2021.2023329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2023329</ArticleId><ArticleId IdType="pmc">PMC8774049</ArticleId><ArticleId IdType="pubmed">34951565</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira I, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599:114&#x2013;9. doi: 10.1038/s41586-021-03944-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03944-y</ArticleId><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesner D, Reuschl AK, Whelan M, Bronzovich T, Haider T, Thorne LG, et al. SARS-CoV-2 evolution influences GBP and IFITM sensitivity. Proc Natl Acad Sci USA. 2023;120:e2212577120. doi: 10.1073/pnas.2212577120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2212577120</ArticleId><ArticleId IdType="pmc">PMC9945951</ArticleId><ArticleId IdType="pubmed">36693093</ArticleId></ArticleIdList></Reference><Reference><Citation>Timilsina U, Umthong S, Ivey EB, Waxman B, Stavrou S. SARS-CoV-2 ORF7a potently inhibits the antiviral effect of the host factor SERINC5. Nat Commun. 2022;13:2935. doi: 10.1038/s41467-022-30609-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30609-9</ArticleId><ArticleId IdType="pmc">PMC9135752</ArticleId><ArticleId IdType="pubmed">35618710</ArticleId></ArticleIdList></Reference><Reference><Citation>Meseguer S, Rubio MP, Lainez B, P&#xe9;rez-Benavente B, P&#xe9;rez-Moraga R, Romera-Giner S, et al. SARS-CoV-2-encoded small RNAs are able to repress the host expression of SERINC5 to facilitate viral replication. Front Microbiol. 2023;14:1066493. doi: 10.3389/fmicb.2023.1066493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2023.1066493</ArticleId><ArticleId IdType="pmc">PMC9978209</ArticleId><ArticleId IdType="pubmed">36876111</ArticleId></ArticleIdList></Reference><Reference><Citation>Usami Y, Wu Y, G&#xf6;ttlinger HG. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature. 2015;526:218&#x2013;23. doi: 10.1038/nature15400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature15400</ArticleId><ArticleId IdType="pmc">PMC4600458</ArticleId><ArticleId IdType="pubmed">26416733</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlman S, Peiris M. Coronavirus research: knowledge gaps and research priorities. Nat Rev Microbiol. 2023;21:125&#x2013;6. doi: 10.1038/s41579-022-00837-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00837-3</ArticleId><ArticleId IdType="pubmed">36792727</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Zhang X, Lei X, Xiao X, Jiao T, Ma R, et al. Sensing of cytoplasmic chromatin by cGAS activates innate immune response in SARS-CoV-2 infection. Signal Transduct Target Ther. 2021;6:382. doi: 10.1038/s41392-021-00800-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00800-3</ArticleId><ArticleId IdType="pmc">PMC8564796</ArticleId><ArticleId IdType="pubmed">34732709</ArticleId></ArticleIdList></Reference><Reference><Citation>Motwani M, Pesiridis S, Fitzgerald KA. DNA sensing by the cGAS&#x2013;STING pathway in health and disease. Nat Rev Genet. 2019;20:657&#x2013;74. doi: 10.1038/s41576-019-0151-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-019-0151-1</ArticleId><ArticleId IdType="pubmed">31358977</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339:786&#x2013;91. doi: 10.1126/science.1232458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232458</ArticleId><ArticleId IdType="pmc">PMC3863629</ArticleId><ArticleId IdType="pubmed">23258413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Z, Damania B. The cGAS-STING defense pathway and its counteraction by viruses. Cell Host Microbe. 2016;19:150&#x2013;8. doi: 10.1016/j.chom.2016.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.01.010</ArticleId><ArticleId IdType="pmc">PMC4755325</ArticleId><ArticleId IdType="pubmed">26867174</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Wei L, Xu F, Zhao F, Huang Y, Fan Z, et al. SARS-CoV-2 spike protein-induced cell fusion activates the cGAS-STING pathway and the interferon response. Sci Signal. 2022;15:eabg8744. doi: 10.1126/scisignal.abg8744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.abg8744</ArticleId><ArticleId IdType="pubmed">35412852</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Zhou F, Zhang L. STING, a critical contributor to SARS-CoV-2 immunopathology. Signal Transduct Target Ther. 2022;7:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8964922</ArticleId><ArticleId IdType="pubmed">35354788</ArticleId></ArticleIdList></Reference><Reference><Citation>Domizio JD, Gulen MF, Saidoune F, Thacker VV, Yatim A, Sharma K, et al. The cGAS-STING pathway drives type I IFN immunopathology in COVID-19. Nature. 2022;603:145&#x2013;51. doi: 10.1038/s41586-022-04421-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04421-w</ArticleId><ArticleId IdType="pmc">PMC8891013</ArticleId><ArticleId IdType="pubmed">35045565</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y, Huang B, Yang Y, Fu X, Fu Z, Xu H, et al. The substrate selectivity of papain-like proteases from human-infecting coronaviruses correlates with innate immune suppression. Sci Signal. 2023;16:eade1985. doi: 10.1126/scisignal.ade1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.ade1985</ArticleId><ArticleId IdType="pubmed">37130166</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Duan L, Huang B, Xiong Y, Zhang G, Huang H. The SARS-CoV-2 papain-like protease suppresses type I interferon responses by deubiquitinating STING. Sci Signal. 2023;16:eadd0082. doi: 10.1126/scisignal.add0082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.add0082</ArticleId><ArticleId IdType="pubmed">37130168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussani R, Schneider E, Zentilin L, Collesi C, Ali H, Braga L, et al. Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. EBioMedicine. 2020;61:103104. doi: 10.1016/j.ebiom.2020.103104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.103104</ArticleId><ArticleId IdType="pmc">PMC7677597</ArticleId><ArticleId IdType="pubmed">33158808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Zheng Y, Niu Z, Zhang B, Wang C, Yao X, et al. SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination. Cell Death Differ. 2021;28:2765&#x2013;77. doi: 10.1038/s41418-021-00782-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-021-00782-3</ArticleId><ArticleId IdType="pmc">PMC8056997</ArticleId><ArticleId IdType="pubmed">33879858</ArticleId></ArticleIdList></Reference><Reference><Citation>Papa G, Mallery DL, Albecka A, Welch LG, Cattin-Ortol&#xe1; J, Luptak J, et al. Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion. PLOS Pathog. 2021;17:e1009246. doi: 10.1371/journal.ppat.1009246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009246</ArticleId><ArticleId IdType="pmc">PMC7861537</ArticleId><ArticleId IdType="pubmed">33493182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai S, Zhang C, Zhuang Z, Zhang S, Ma L, Yang S, et al. Phase-separated nucleocapsid protein of SARS-CoV-2 suppresses cGAS-DNA recognition by disrupting cGAS-G3BP1 complex. Signal Transduct Target Ther. 2023;8:170. doi: 10.1038/s41392-023-01420-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01420-9</ArticleId><ArticleId IdType="pmc">PMC10131525</ArticleId><ArticleId IdType="pubmed">37100798</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog. 2013;9:e1003565. doi: 10.1371/journal.ppat.1003565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003565</ArticleId><ArticleId IdType="pmc">PMC3744431</ArticleId><ArticleId IdType="pubmed">23966862</ArticleId></ArticleIdList></Reference><Reference><Citation>Amicone M, Borges V, Alves MJ, Isidro J, Z&#xe9;-Z&#xe9; L, Duarte S, et al. Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. Evol Med Public Health. 2022;10:142&#x2013;55. doi: 10.1093/emph/eoac010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emph/eoac010</ArticleId><ArticleId IdType="pmc">PMC8996265</ArticleId><ArticleId IdType="pubmed">35419205</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22:757&#x2013;73. doi: 10.1038/s41576-021-00408-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-021-00408-x</ArticleId><ArticleId IdType="pmc">PMC8447121</ArticleId><ArticleId IdType="pubmed">34535792</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023;21:361&#x2013;79. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet. 2008;9:267&#x2013;76. doi: 10.1038/nrg2323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg2323</ArticleId><ArticleId IdType="pubmed">18319742</ArticleId></ArticleIdList></Reference><Reference><Citation>Slotkin W, Nishikura K. Adenosine-to-inosine RNA editing and human disease. Genome Med. 2013;5:105. doi: 10.1186/gm508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gm508</ArticleId><ArticleId IdType="pmc">PMC3979043</ArticleId><ArticleId IdType="pubmed">24289319</ArticleId></ArticleIdList></Reference><Reference><Citation>Picardi E, Manzari C, Mastropasqua F, Aiello I, D'Erchia AM, Pesole G. Profiling RNA editing in human tissues: towards the inosinome Atlas. Sci Rep. 2015;5:14941. doi: 10.1038/srep14941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep14941</ArticleId><ArticleId IdType="pmc">PMC4598827</ArticleId><ArticleId IdType="pubmed">26449202</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio S, Martignano F, Torcia MG, Mattiuz G, Conticello SG. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. Sci Adv. 2020;6:eabb5813. doi: 10.1126/sciadv.abb5813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abb5813</ArticleId><ArticleId IdType="pmc">PMC7299625</ArticleId><ArticleId IdType="pubmed">32596474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Calabrese P, Wang S, Qin C, Rao Y, Feng P, et al. The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness. bioRxiv 2021.12.18.473309. 2022. 10.1101/2021.12.18.473309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9470679</ArticleId><ArticleId IdType="pubmed">36100631</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45:970&#x2013;6. doi: 10.1038/ng.2702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2702</ArticleId><ArticleId IdType="pmc">PMC3789062</ArticleId><ArticleId IdType="pubmed">23852170</ArticleId></ArticleIdList></Reference><Reference><Citation>Asaoka M, Ishikawa T, Takabe K, Patnaik SK. APOBEC3-mediated RNA editing in breast cancer is associated with heightened immune activity and improved survival. Int J Mol Sci. 2019;20:5621. doi: 10.3390/ijms20225621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20225621</ArticleId><ArticleId IdType="pmc">PMC6888598</ArticleId><ArticleId IdType="pubmed">31717692</ArticleId></ArticleIdList></Reference><Reference><Citation>Azgari C, Kilinc Z, Turhan B, Circi D, Adebali O. The mutation profile of SARS-CoV-2 is primarily shaped by the host antiviral defense. Viruses. 2021;13:394. doi: 10.3390/v13030394.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030394</ArticleId><ArticleId IdType="pmc">PMC7999997</ArticleId><ArticleId IdType="pubmed">33801257</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X, Luo Y, Li H, Guo X, Chen H, Ji X, et al. RNA editing increases the nucleotide diversity of SARS-CoV-2 in human host cells. PLoS Genet. 2022;18:e1010130. doi: 10.1371/journal.pgen.1010130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1010130</ArticleId><ArticleId IdType="pmc">PMC9000099</ArticleId><ArticleId IdType="pubmed">35353808</ArticleId></ArticleIdList></Reference><Reference><Citation>Graudenzi A, Maspero D, Angaroni F, Piazza R, Ramazzotti D. Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity. iScience. 2021;24:102116. doi: 10.1016/j.isci.2021.102116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.102116</ArticleId><ArticleId IdType="pmc">PMC7842190</ArticleId><ArticleId IdType="pubmed">33532709</ArticleId></ArticleIdList></Reference><Reference><Citation>Evangelou K, Veroutis D, Paschalaki K, Foukas PG, Lagopati N, Dimitriou M, et al. Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. Eur Respir J. 2022;60:2102951. doi: 10.1183/13993003.02951-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02951-2021</ArticleId><ArticleId IdType="pmc">PMC8796696</ArticleId><ArticleId IdType="pubmed">35086840</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakasiliotis I, Lagopati N, Evangelou K, Gorgoulis VG. Cellular senescence as a source of SARS-CoV-2 quasispecies. FEBS J. 2023;290:1384&#x2013;92. doi: 10.1111/febs.16230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.16230</ArticleId><ArticleId IdType="pubmed">34653312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruis C, Peacock TP, Polo LM, Masone D, Alvarez MS, Hinrichs AS, et al. A lung-specific mutational signature enables inference of viral and bacterial respiratory niche. Microb Genom. 2023;9:mgen001018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10272861</ArticleId><ArticleId IdType="pubmed">37185044</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel CE. Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses. J Biol Chem. 2019;294:1710&#x2013;20. doi: 10.1074/jbc.TM118.004166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.TM118.004166</ArticleId><ArticleId IdType="pmc">PMC6364763</ArticleId><ArticleId IdType="pubmed">30710018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, Silke JR, Aris P, Xia X. Coronavirus genomes carry the signatures of their habitats. PloS One. 2020;15:e0244025. doi: 10.1371/journal.pone.0244025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244025</ArticleId><ArticleId IdType="pmc">PMC7755226</ArticleId><ArticleId IdType="pubmed">33351847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S, Patnaik SK, Taggart RT, Kannisto ED, Enriquez SM, Gollnick P, et al. APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages. Nat Commun. 2015;6:6881. doi: 10.1038/ncomms7881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7881</ArticleId><ArticleId IdType="pmc">PMC4411297</ArticleId><ArticleId IdType="pubmed">25898173</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauernfried S, Scherr MJ, Pichlmair A, Duderstadt KE, Hornung V. Human NLRP1 is a sensor for double-stranded RNA. Science. 2021;371:eabd0811. doi: 10.1126/science.abd0811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0811</ArticleId><ArticleId IdType="pubmed">33243852</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmonds P, Ansari MA. Extensive C-&#x2009;&gt;&#x2009;U transition biases in the genomes of a wide range of mammalian RNA viruses; potential associations with transcriptional mutations, damage- or host-mediated editing of viral RNA. PLoS Pathog. 2021;17:e1009596. doi: 10.1371/journal.ppat.1009596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009596</ArticleId><ArticleId IdType="pmc">PMC8195396</ArticleId><ArticleId IdType="pubmed">34061905</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng AZ, Moraes SN, Shaban NM, Fanunza E, Bierle CJ, Southern PJ, et al. APOBECs and herpesviruses. Viruses. 2021;13:390. doi: 10.3390/v13030390.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13030390</ArticleId><ArticleId IdType="pmc">PMC7998176</ArticleId><ArticleId IdType="pubmed">33671095</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakata Y, Ode H, Kubota M, Kasahara T, Matsuoka K, Sugimoto A, et al. Cellular APOBEC3A deaminase drives mutations in the SARS-CoV-2 genome. Nucleic Acids Res. 2023;51:783&#x2013;95. doi: 10.1093/nar/gkac1238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac1238</ArticleId><ArticleId IdType="pmc">PMC9881129</ArticleId><ArticleId IdType="pubmed">36610792</ArticleId></ArticleIdList></Reference><Reference><Citation>McDaniel YZ, Wang D, Love RP, Adolph MB, Mohammadzadeh N, Chelico L, et al. Deamination hotspots among APOBEC3 family members are defined by both target site sequence context and ssDNA secondary structure. Nucleic Acids Res. 2020;48:1353&#x2013;71. doi: 10.1093/nar/gkz1164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1164</ArticleId><ArticleId IdType="pmc">PMC7026630</ArticleId><ArticleId IdType="pubmed">31943071</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice AM, Castillo Morales A, Ho AT, Mordstein C, M&#xfc;hlhausen S, Watson S, et al. Evidence for strong mutation bias toward, and selection against, U content in SARS-CoV-2: implications for vaccine design. Mol Biol Evol. 2021;38:67&#x2013;83. doi: 10.1093/molbev/msaa188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/msaa188</ArticleId><ArticleId IdType="pmc">PMC7454790</ArticleId><ArticleId IdType="pubmed">32687176</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dorp L, Richard D, Tan C, Shaw LP, Acman M, Balloux F. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nat Commun. 2020;11:5986. doi: 10.1038/s41467-020-19818-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19818-2</ArticleId><ArticleId IdType="pmc">PMC7688939</ArticleId><ArticleId IdType="pubmed">33239633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratcliff J, Simmonds P. Potential APOBEC-mediated RNA editing of the genomes of SARS-CoV-2 and other coronaviruses and its impact on their longer term evolution. Virology. 2021;556:62&#x2013;72. doi: 10.1016/j.virol.2020.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2020.12.018</ArticleId><ArticleId IdType="pmc">PMC7831814</ArticleId><ArticleId IdType="pubmed">33545556</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmonds P. Rampant C&#x2009;&#x2192;&#x2009;U hypermutation in the genomes of SARS-CoV-2 and other coronaviruses: causes and consequences for their short- and long-term evolutionary trajectories. mSphere. 2020;5:e00408&#x2013;20. doi: 10.1128/mSphere.00408-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00408-20</ArticleId><ArticleId IdType="pmc">PMC7316492</ArticleId><ArticleId IdType="pubmed">32581081</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi K, Kim SY, Bleazard T, Kim T, Youk J, Ju YS. Mutational spectrum of SARS-CoV-2 during the global pandemic. Exp Mol Med. 2021;53:1229&#x2013;37. doi: 10.1038/s12276-021-00658-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00658-z</ArticleId><ArticleId IdType="pmc">PMC8393781</ArticleId><ArticleId IdType="pubmed">34453107</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Li X, Qi R, Billiar T. RNA editing, ADAR1, and the innate immune response. Genes. 2017;8:41. doi: 10.3390/genes8010041.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes8010041</ArticleId><ArticleId IdType="pmc">PMC5295035</ArticleId><ArticleId IdType="pubmed">28106799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartner JC, Walkley CR, Lu J, Orkin SH. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol. 2009;10:109&#x2013;15. doi: 10.1038/ni.1680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1680</ArticleId><ArticleId IdType="pmc">PMC2701568</ArticleId><ArticleId IdType="pubmed">19060901</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, Calis J, Wu X, Sun T, Yu Y, Sarbanes SL, et al. Human ADAR1 prevents endogenous RNA from triggering translational shutdown. Cell. 2018;172:811&#x2013;24.e14. doi: 10.1016/j.cell.2017.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.12.038</ArticleId><ArticleId IdType="pmc">PMC5831367</ArticleId><ArticleId IdType="pubmed">29395325</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, Szynkiewicz M, et al. Mutations in ADAR1 cause Aicardi-Gouti&#xe8;res syndrome associated with a type I interferon signature. Nat Genet. 2012;44:1243&#x2013;8. doi: 10.1038/ng.2414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2414</ArticleId><ArticleId IdType="pmc">PMC4154508</ArticleId><ArticleId IdType="pubmed">23001123</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812&#x2013;27.e19. doi: 10.1016/j.cell.2020.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.043</ArticleId><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourier T, Sadykov M, Carr MJ, Gonzalez G, Hall WW, Pain A. Host-directed editing of the SARS-CoV-2 genome. Biochem Biophys Res Commun. 2021;538:35&#x2013;9. doi: 10.1016/j.bbrc.2020.10.092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.092</ArticleId><ArticleId IdType="pmc">PMC7643664</ArticleId><ArticleId IdType="pubmed">33234239</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N, Lareau CA, Keshishian H, Ganskih S, Schneider C, Hennig T, et al. The SARS-CoV-2 RNA-protein interactome in infected human cells. Nat Microbiol. 2021;6:339&#x2013;53. doi: 10.1038/s41564-020-00846-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00846-z</ArticleId><ArticleId IdType="pmc">PMC7906908</ArticleId><ArticleId IdType="pubmed">33349665</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaller CK, George CX, Samuel CE. Adenosine deaminases acting on RNA (ADARs) and viral infections. Annu Rev Virol. 2021;8:239&#x2013;64. doi: 10.1146/annurev-virology-091919-065320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-091919-065320</ArticleId><ArticleId IdType="pubmed">33882257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringlander J, Fingal J, Kann H, Prakash K, Rydell G, Andersson M, et al. Impact of ADAR-induced editing of minor viral RNA populations on replication and transmission of SARS-CoV-2. Proc Natl Acad Sci USA. 2022;119:e2112663119. doi: 10.1073/pnas.2112663119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2112663119</ArticleId><ArticleId IdType="pmc">PMC8833170</ArticleId><ArticleId IdType="pubmed">35064076</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao G, Guo X, Goff SP. Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science. 2002;297:1703&#x2013;6. doi: 10.1126/science.1074276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1074276</ArticleId><ArticleId IdType="pubmed">12215647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Gao G. ZAP-mediated mRNA degradation. RNA Biol. 2008;5:65&#x2013;67. doi: 10.4161/rna.5.2.6044.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/rna.5.2.6044</ArticleId><ArticleId IdType="pubmed">18418085</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Wang X, Tu F, Wang Q, Fan Z, Gao G. TRIM25 is required for the antiviral activity of zinc finger antiviral protein. J Virol. 2017;91:e00088&#x2013;17. doi: 10.1128/JVI.00088-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00088-17</ArticleId><ArticleId IdType="pmc">PMC5391446</ArticleId><ArticleId IdType="pubmed">28202764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ficarelli M, Wilson H, Pedro Gal&#xe3;o R, Mazzon M, Antzin-Anduetza I, Marsh M, et al. KHNYN is essential for the zinc finger antiviral protein (ZAP) to restrict HIV-1 containing clustered CpG dinucleotides. eLife. 2019;8:e46767. doi: 10.7554/eLife.46767.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.46767</ArticleId><ArticleId IdType="pmc">PMC6615859</ArticleId><ArticleId IdType="pubmed">31284899</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MM, Lau Z, Cheung P, Aguilar EG, Schneider WM, Bozzacco L, et al. TRIM25 enhances the antiviral action of zinc-finger antiviral protein (ZAP) PLoS Pathog. 2017;13:e1006145. doi: 10.1371/journal.ppat.1006145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006145</ArticleId><ArticleId IdType="pmc">PMC5245905</ArticleId><ArticleId IdType="pubmed">28060952</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue G, Braczyk K, Gon&#xe7;alves-Carneiro D, Dawidziak DM, Sanchez K, Ong H, et al. Poly(ADP-ribose) potentiates ZAP antiviral activity. PLOS Pathog. 2022;18:e1009202. doi: 10.1371/journal.ppat.1009202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009202</ArticleId><ArticleId IdType="pmc">PMC8853533</ArticleId><ArticleId IdType="pubmed">35130321</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel W, Noerenberg M, Cerikan B, Chen H, J&#xe4;rvelin AI, Kammoun M, et al. Global analysis of protein-RNA interactions in SARS-CoV-2-infected cells reveals key regulators of infection. Mol Cell. 2021;81:2851&#x2013;67.e7. doi: 10.1016/j.molcel.2021.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2021.05.023</ArticleId><ArticleId IdType="pmc">PMC8142890</ArticleId><ArticleId IdType="pubmed">34118193</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Goyal N, Saranathan N, Dhamija S, Saraswat S, Menon MB, et al. The slowing rate of CpG depletion in SARS-CoV-2 genomes is consistent with adaptations to the human host. Mol Biol Evol. 2022;39:msac029. doi: 10.1093/molbev/msac029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/msac029</ArticleId><ArticleId IdType="pmc">PMC8892944</ArticleId><ArticleId IdType="pubmed">35134218</ArticleId></ArticleIdList></Reference><Reference><Citation>Green DR. The end and after: how dying cells impact the living organism. Immunity. 2011;35:441&#x2013;4. doi: 10.1016/j.immuni.2011.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.10.003</ArticleId><ArticleId IdType="pubmed">22035836</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine B, Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol. 2007;7:767&#x2013;77. doi: 10.1038/nri2161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2161</ArticleId><ArticleId IdType="pmc">PMC7097190</ArticleId><ArticleId IdType="pubmed">17767194</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Tu S, Ding L, Jin M, Chen H, Zhou H. The role of autophagy in viral infections. J Biomed Sci. 2023;30:5. doi: 10.1186/s12929-023-00899-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-023-00899-2</ArticleId><ArticleId IdType="pmc">PMC9846652</ArticleId><ArticleId IdType="pubmed">36653801</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y, Bowman JW, Jung JU. Autophagy during viral infection&#x2014;a double-edged sword. Nat Rev Microbiol. 2018;16:341&#x2013;54. doi: 10.1038/s41579-018-0003-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0003-6</ArticleId><ArticleId IdType="pmc">PMC6907743</ArticleId><ArticleId IdType="pubmed">29556036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparrer KMJ, Gableske S, Zurenski MA, Parker ZM, Full F, Baumgart GJ, et al. TRIM23 mediates virus-induced autophagy via activation of TBK1. Nat Microbiol. 2017;2:1543&#x2013;57. doi: 10.1038/s41564-017-0017-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-017-0017-2</ArticleId><ArticleId IdType="pmc">PMC5658249</ArticleId><ArticleId IdType="pubmed">28871090</ArticleId></ArticleIdList></Reference><Reference><Citation>Staring J, von Castelmur E, Blomen VA, van den Hengel LG, Brockmann M, Baggen J, et al. PLA2G16 represents a switch between entry and clearance of Picornaviridae. Nature. 2017;541:412&#x2013;6. doi: 10.1038/nature21032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21032</ArticleId><ArticleId IdType="pubmed">28077878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ait-Goughoulte M, Kanda T, Meyer K, Ryerse JS, Ray RB, Ray R. Hepatitis C virus genotype 1a growth and induction of autophagy. J Virol. 2008;82:2241&#x2013;9. doi: 10.1128/JVI.02093-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02093-07</ArticleId><ArticleId IdType="pmc">PMC2258951</ArticleId><ArticleId IdType="pubmed">18077704</ArticleId></ArticleIdList></Reference><Reference><Citation>Su J, Shen S, Hu Y, Chen S, Cheng L, Cai Y, et al. SARS-CoV-2 ORF3a inhibits cGAS-STING-mediated autophagy flux and antiviral function. J Med Virol. 2023;95:e28175. doi: 10.1002/jmv.28175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28175</ArticleId><ArticleId IdType="pmc">PMC9538343</ArticleId><ArticleId IdType="pubmed">36163413</ArticleId></ArticleIdList></Reference><Reference><Citation>Han L, Zheng Y, Deng J, Nan ML, Xiao Y, Zhuang MW, et al. SARS&#x2010;CoV&#x2010;2 ORF10 antagonizes STING&#x2010;dependent interferon activation and autophagy. J Med Virol. 2022;94:5174&#x2013;88. doi: 10.1002/jmv.27965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27965</ArticleId><ArticleId IdType="pmc">PMC9350412</ArticleId><ArticleId IdType="pubmed">35765167</ArticleId></ArticleIdList></Reference><Reference><Citation>Koepke L, Hirschenberger M, Hayn M, Kirchhoff F, Sparrer KM. Manipulation of autophagy by SARS-CoV-2 proteins. Autophagy. 2021;17:2659&#x2013;61. doi: 10.1080/15548627.2021.1953847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2021.1953847</ArticleId><ArticleId IdType="pmc">PMC8496524</ArticleId><ArticleId IdType="pubmed">34281462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, Shu T, Wu D, Mu J, Wang C, Huang M, et al. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. Cell Mol Immunol. 2020;17:881&#x2013;3. doi: 10.1038/s41423-020-0485-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0485-9</ArticleId><ArticleId IdType="pmc">PMC7301057</ArticleId><ArticleId IdType="pubmed">32555321</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao G, Zhao H, Li Y, Ji M, Chen Y, Shi Y, et al. ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation. Dev Cell. 2021;56:427&#x2013;42.e5. doi: 10.1016/j.devcel.2020.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2020.12.010</ArticleId><ArticleId IdType="pmc">PMC7832235</ArticleId><ArticleId IdType="pubmed">33422265</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Sun H, Pei R, Mao B, Zhao Z, Li H, et al. The SARS-CoV-2 protein ORF3a inhibits fusion of autophagosomes with lysosomes. Cell Discov. 2021;7:1&#x2013;12. doi: 10.1038/s41421-021-00268-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00268-z</ArticleId><ArticleId IdType="pmc">PMC8096138</ArticleId><ArticleId IdType="pubmed">33947832</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozzi A, Oldani M, Forcella ME, Vantaggiato C, Cappelletti G, Pontremoli C, et al. SARS-CoV-2 ORF3c impairs mitochondrial respiratory metabolism, oxidative stress, and autophagic flux. iScience. 2023;26:107118. doi: 10.1016/j.isci.2023.107118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.107118</ArticleId><ArticleId IdType="pmc">PMC10265927</ArticleId><ArticleId IdType="pubmed">37361873</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Wu H, Yao X, Zhang D, Zhou Y, Fu B, et al. Pyroptotic macrophages stimulate the SARS-CoV-2-associated cytokine storm. Cell Mol Immunol. 2021;18:1305&#x2013;7. doi: 10.1038/s41423-021-00665-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00665-0</ArticleId><ArticleId IdType="pmc">PMC7976727</ArticleId><ArticleId IdType="pubmed">33742186</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Liu Y, Huang Z, Xu W, Hu W, Yi L, et al. SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ. 2022;29:1240&#x2013;54. doi: 10.1038/s41418-021-00916-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-021-00916-7</ArticleId><ArticleId IdType="pmc">PMC9177730</ArticleId><ArticleId IdType="pubmed">34997207</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C, Crespo &#xc2;, Ranjbar S, de Lacerda LB, Lewandrowski M, Ingber J, et al. Fc&#x3b3;R-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022;606:576&#x2013;84. doi: 10.1038/s41586-022-04702-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04702-4</ArticleId><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E, Qu R, Junqueira C, Kaffe E, Mirza H, Zhao J, et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature. 2022;606:585&#x2013;93. doi: 10.1038/s41586-022-04802-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04802-1</ArticleId><ArticleId IdType="pmc">PMC9288243</ArticleId><ArticleId IdType="pubmed">35483404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Zhu F, Zhao M, Shao F, Yu D, Ma J, et al. SARS-CoV-2 nucleocapsid suppresses host pyroptosis by blocking Gasdermin D cleavage. EMBO J. 2021;40:e108249. doi: 10.15252/embj.2021108249.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021108249</ArticleId><ArticleId IdType="pmc">PMC8420271</ArticleId><ArticleId IdType="pubmed">34296442</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6:1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005494</ArticleId><ArticleId IdType="pubmed">33776057</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D-M, Geng T-T, Harrison AG, Wang P-H. Differential roles of RIG-I like receptors in SARS-CoV-2 infection. Mil Med Res. 2021;8:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8421188</ArticleId><ArticleId IdType="pubmed">34488908</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y-Z, Wang SY, Zheng ZQ, Yi H, Li WW, Xu ZS, et al. SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response. Cell Mol Immunol. 2021;18:613&#x2013;20. doi: 10.1038/s41423-020-00571-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00571-x</ArticleId><ArticleId IdType="pmc">PMC7588591</ArticleId><ArticleId IdType="pubmed">33110251</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Shi Y, Pan X, Wu S, Hou R, Zhang Y, et al. SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO. Cell Rep. 2021;34:108761. doi: 10.1016/j.celrep.2021.108761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108761</ArticleId><ArticleId IdType="pmc">PMC7857071</ArticleId><ArticleId IdType="pubmed">33567255</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Hou P, Ma W, Wang X, Wang H, Yu Z, et al. SARS-CoV-2 ORF10 suppresses the antiviral innate immune response by degrading MAVS through mitophagy. Cell Mol Immunol. 2022;19:67&#x2013;78. doi: 10.1038/s41423-021-00807-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00807-4</ArticleId><ArticleId IdType="pmc">PMC8628139</ArticleId><ArticleId IdType="pubmed">34845370</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart H, Lu Y, O'Keefe S, Valpadashi A, Cruz-Zaragoza LD, Michel HA, et al. The SARS-CoV-2 protein ORF3c is a mitochondrial modulator of innate immunity. iScience. 2023;26:108080. doi: 10.1016/j.isci.2023.108080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.108080</ArticleId><ArticleId IdType="pmc">PMC10583119</ArticleId><ArticleId IdType="pubmed">37860693</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T, Sato S, Sotoyama Y, Orba Y, Sawa H, Yamauchi H, et al. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat Immunol. 2021;22:820&#x2013;8. doi: 10.1038/s41590-021-00942-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00942-0</ArticleId><ArticleId IdType="pubmed">33976430</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523&#x2013;34. doi: 10.1038/nrmicro.2016.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2016.81</ArticleId><ArticleId IdType="pmc">PMC7097822</ArticleId><ArticleId IdType="pubmed">27344959</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder S, Pott F, Niemeyer D, Veith T, Richter A, Muth D, et al. Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics. Lancet Microbe. 2021;2:e210&#x2013;8. doi: 10.1016/S2666-5247(21)00027-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00027-6</ArticleId><ArticleId IdType="pmc">PMC8096348</ArticleId><ArticleId IdType="pubmed">33969329</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, M&#xf8;ller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036&#x2013;45.e9. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno Y, Kimura I, Uriu K, Fukushi M, Irie T, Koyanagi Y, et al. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep. 2020;32:108185. doi: 10.1016/j.celrep.2020.108185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108185</ArticleId><ArticleId IdType="pmc">PMC7473339</ArticleId><ArticleId IdType="pubmed">32941788</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J-Y, Liao CH, Wang Q, Tan YJ, Luo R, Qiu Y, et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res. 2020;286:198074. doi: 10.1016/j.virusres.2020.198074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2020.198074</ArticleId><ArticleId IdType="pmc">PMC7309931</ArticleId><ArticleId IdType="pubmed">32589897</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen C-K, Lam JY, Wong WM, Mak LF, Wang X, Chu H, et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg Microbes Infect. 2020;9:1418&#x2013;28. doi: 10.1080/22221751.2020.1780953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1780953</ArticleId><ArticleId IdType="pmc">PMC7473193</ArticleId><ArticleId IdType="pubmed">32529952</ArticleId></ArticleIdList></Reference><Reference><Citation>Miorin L, Kehrer T, Sanchez-Aparicio MT, Zhang K, Cohen P, Patel RS, et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci USA. 2020;117:28344&#x2013;54. doi: 10.1073/pnas.2016650117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2016650117</ArticleId><ArticleId IdType="pmc">PMC7668094</ArticleId><ArticleId IdType="pubmed">33097660</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid F, Suleman M, Shah A, Dzakah EE, Wang H, Chen S, et al. Mutations in SARS-CoV-2 ORF8 altered the bonding network with interferon regulatory factor 3 to evade host immune system. Front Microbiol. 2021;12:703145. doi: 10.3389/fmicb.2021.703145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.703145</ArticleId><ArticleId IdType="pmc">PMC8322779</ArticleId><ArticleId IdType="pubmed">34335535</ArticleId></ArticleIdList></Reference><Reference><Citation>Gori Savellini G, Anichini G, Cusi MG. SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells. Virus Res. 2023;332:199134. doi: 10.1016/j.virusres.2023.199134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2023.199134</ArticleId><ArticleId IdType="pmc">PMC10191105</ArticleId><ArticleId IdType="pubmed">37192725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom. Lancet Reg Health&#x2014;Eur. 2023;25:100556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9742675</ArticleId><ArticleId IdType="pubmed">36530491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Ishida R, Strilets T, Cole J, Lopez-Orozco J, Fayad N, et al. SARS-CoV-2 nonstructural protein 1 inhibits the interferon response by causing depletion of key host signaling factors. J Virol. 2021;95:e0026621. doi: 10.1128/JVI.00266-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00266-21</ArticleId><ArticleId IdType="pmc">PMC8316110</ArticleId><ArticleId IdType="pubmed">34110264</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Lee JH, Parker ZM, Acharya D, Chiang JJ, van Gent M, et al. ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. Nat Microbiol. 2021;6:467&#x2013;78. doi: 10.1038/s41564-021-00884-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00884-1</ArticleId><ArticleId IdType="pmc">PMC8103894</ArticleId><ArticleId IdType="pubmed">33727702</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587:657&#x2013;62. doi: 10.1038/s41586-020-2601-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2601-5</ArticleId><ArticleId IdType="pmc">PMC7116779</ArticleId><ArticleId IdType="pubmed">32726803</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhammad YMO, Kashipathy MM, Roy A, Gagn&#xe9; JP, McDonald P, Gao P, et al. The SARS-CoV-2 conserved macrodomain is a mono-ADP-ribosylhydrolase. J Virol. 2021;95:e01969&#x2013;20. doi: 10.1128/JVI.01969-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01969-20</ArticleId><ArticleId IdType="pmc">PMC7925111</ArticleId><ArticleId IdType="pubmed">33158944</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr AR, Athmer J, Channappanavar R, Phillips JM, Meyerholz DK, Perlman S. The nsp3 macrodomain promotes virulence in mice with coronavirus-induced encephalitis. J Virol. 2014;89:1523&#x2013;36. doi: 10.1128/JVI.02596-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02596-14</ArticleId><ArticleId IdType="pmc">PMC4300739</ArticleId><ArticleId IdType="pubmed">25428866</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr AR, Channappanavar R, Jankevicius G, Fett C, Zhao J, Athmer J, et al. The conserved coronavirus macrodomain promotes virulence and suppresses the innate immune response during severe acute respiratory syndrome coronavirus infection. mBio. 2016;7:e01721&#x2013;16. doi: 10.1128/mBio.01721-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01721-16</ArticleId><ArticleId IdType="pmc">PMC5156301</ArticleId><ArticleId IdType="pubmed">27965448</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha TY, Suryawanshi RK, Chen IP, Correy GJ, McCavitt-Malvido M, O'Leary PC, et al. A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo. PLOS Pathog. 2023;19:e1011614. doi: 10.1371/journal.ppat.1011614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1011614</ArticleId><ArticleId IdType="pmc">PMC10499221</ArticleId><ArticleId IdType="pubmed">37651466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega Granda O, Alvarez K, Mate-Perez MJ, Canard B, Ferron F, Rabah N. Macro1 domain residue F156: a hallmark of SARS-CoV-2 de-MARylation specificity. Virology. 2023;587:109845. doi: 10.1016/j.virol.2023.109845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2023.109845</ArticleId><ArticleId IdType="pubmed">37517331</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoch NC. Host ADP-ribosylation and the SARS-CoV-2 macrodomain. Biochem Soc Trans. 2021;49:1711&#x2013;21. doi: 10.1042/BST20201212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20201212</ArticleId><ArticleId IdType="pmc">PMC8421052</ArticleId><ArticleId IdType="pubmed">34351418</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhammad YM, Parthasarathy S, Ghimire R, O'Connor JJ, Kerr CM, Pfannenstiel JJ, et al. SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in mice. BioRxiv Prepr Serv Biol. 2023.04.06.535927. 2023. 10.1101/2023.04.06.535927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10468617</ArticleId><ArticleId IdType="pubmed">37607224</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Mao D, Roswit WT, Jin X, Patel AC, Patel DA, et al. PARP9-DTX3L ubiquitin ligase targets host histone H2BJ and viral 3C protease to enhance interferon signaling and control viral infection. Nat Immunol. 2015;16:1215&#x2013;27. doi: 10.1038/ni.3279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3279</ArticleId><ArticleId IdType="pmc">PMC4653074</ArticleId><ArticleId IdType="pubmed">26479788</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H, Cao Z, Xie X, Zhang X, Chen JY, Wang H, et al. Evasion of type I interferon by SARS-CoV-2. Cell Rep. 2020;33:108234. doi: 10.1016/j.celrep.2020.108234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108234</ArticleId><ArticleId IdType="pmc">PMC7501843</ArticleId><ArticleId IdType="pubmed">32979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Zhang X, Wang F, Wang P, Kuang E, Li X. Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2. 2020.08.12.247767. 2020. Preprint at 10.1101/2020.08.12.247767.</Citation></Reference><Reference><Citation>Madiraju C, Novack JP, Reed JC, Matsuzawa S. K63 ubiquitination in immune signaling. Trends Immunol. 2022;43:148&#x2013;62. doi: 10.1016/j.it.2021.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2021.12.005</ArticleId><ArticleId IdType="pmc">PMC8755460</ArticleId><ArticleId IdType="pubmed">35033428</ArticleId></ArticleIdList></Reference><Reference><Citation>Neches RY, Kyrpides NC, Ouzounis CA. Atypical divergence of SARS-CoV-2 Orf8 from Orf7a within the coronavirus lineage suggests potential stealthy viral strategies in immune evasion. mBio. 2021;12. 10.1128/mbio.03014-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845636</ArticleId><ArticleId IdType="pubmed">33468697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan SS, Aljabali A, Panda PK, Ghosh S, Attrish D, Choudhury PP, et al. A unique view of SARS-CoV-2 through the lens of ORF8 protein. Comput Biol Med. 2021;133:104380. doi: 10.1016/j.compbiomed.2021.104380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2021.104380</ArticleId><ArticleId IdType="pmc">PMC8049180</ArticleId><ArticleId IdType="pubmed">33872970</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Chen Y, Li Y, Huang F, Luo B, Yuan Y, et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-&#x399;. Proc Natl Acad Sci USA. 2021;118:e2024202118. doi: 10.1073/pnas.2024202118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024202118</ArticleId><ArticleId IdType="pmc">PMC8201919</ArticleId><ArticleId IdType="pubmed">34021074</ArticleId></ArticleIdList></Reference><Reference><Citation>Muth D, Corman VM, Roth H, Binger T, Dijkman R, Gottula LT, et al. Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission. Sci Rep. 2018;8:15177. doi: 10.1038/s41598-018-33487-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33487-8</ArticleId><ArticleId IdType="pmc">PMC6181990</ArticleId><ArticleId IdType="pubmed">30310104</ArticleId></ArticleIdList></Reference><Reference><Citation>Arduini A, Laprise F, Liang C. SARS-CoV-2 ORF8: a rapidly evolving immune and viral modulator in COVID-19. Viruses. 2023;15:871. doi: 10.3390/v15040871.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040871</ArticleId><ArticleId IdType="pmc">PMC10141009</ArticleId><ArticleId IdType="pubmed">37112851</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinjamuri S, Li L, Bouvier M. SARS-CoV-2 ORF8: one protein, seemingly one structure, and many functions. Front Immunol. 2022;13:1035559. doi: 10.3389/fimmu.2022.1035559.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1035559</ArticleId><ArticleId IdType="pmc">PMC9637571</ArticleId><ArticleId IdType="pubmed">36353628</ArticleId></ArticleIdList></Reference><Reference><Citation>Young BE, Fong SW, Chan YH, Mak TM, Ang LW, Anderson DE, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet. 2020;396:603&#x2013;11. doi: 10.1016/S0140-6736(20)31757-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31757-8</ArticleId><ArticleId IdType="pmc">PMC7434477</ArticleId><ArticleId IdType="pubmed">32822564</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangavarapu K, Latif AA, Mullen JL, Alkuzweny M, Hufbauer E, Tsueng G, et al. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Nat Methods. 2023;20:512&#x2013;22. doi: 10.1038/s41592-023-01769-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-023-01769-3</ArticleId><ArticleId IdType="pmc">PMC10399614</ArticleId><ArticleId IdType="pubmed">36823332</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira F. SARS-CoV-2 variants combining spike mutations and the absence of ORF8 may be more transmissible and require close monitoring. Biochem Biophys Res Commun. 2021;550:8&#x2013;14. doi: 10.1016/j.bbrc.2021.02.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.02.080</ArticleId><ArticleId IdType="pmc">PMC7906533</ArticleId><ArticleId IdType="pubmed">33676232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Xia T, Shin WJ, Yu KM, Jung W, Herrmann A, et al. Viral mimicry of interleukin-17A by SARS-CoV-2 ORF8. mBio. 2022;13:e0040222. doi: 10.1128/mbio.00402-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00402-22</ArticleId><ArticleId IdType="pmc">PMC9040823</ArticleId><ArticleId IdType="pubmed">35343786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kee J, Thudium S, Renner DM, Glastad K, Palozola K, Zhang Z, et al. SARS-CoV-2 disrupts host epigenetic regulation via histone mimicry. Nature. 2022;610:381&#x2013;8. doi: 10.1038/s41586-022-05282-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05282-z</ArticleId><ArticleId IdType="pmc">PMC9533993</ArticleId><ArticleId IdType="pubmed">36198800</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhari AM, Singh I, Joshi M, Patel A, Joshi C. Defective ORF8 dimerization in SARS-CoV-2 delta variant leads to a better adaptive immune response due to abrogation of ORF8-MHC1 interaction. Mol Divers. 2023;27:45&#x2013;57. doi: 10.1007/s11030-022-10405-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11030-022-10405-9</ArticleId><ArticleId IdType="pmc">PMC8893242</ArticleId><ArticleId IdType="pubmed">35243596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim I-J, Lee YH, Khalid MM, Chen IP, Zhang Y, Ott M, et al. SARS-CoV-2 protein ORF8 limits expression levels of Spike antigen and facilitates immune evasion of infected host cells. J Biol Chem. 2023;299:104955. doi: 10.1016/j.jbc.2023.104955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.104955</ArticleId><ArticleId IdType="pmc">PMC10289268</ArticleId><ArticleId IdType="pubmed">37354973</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid F, Dzakah EE, Wang H, Tang S. The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta. Virus Res. 2021;296:198350. doi: 10.1016/j.virusres.2021.198350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2021.198350</ArticleId><ArticleId IdType="pmc">PMC7897408</ArticleId><ArticleId IdType="pubmed">33626380</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Wang X, Sun Y, Zhao H, Cheng F, Wang J, et al. SARS-CoV-2 ORF8 reshapes the ER through forming mixed disulfides with ER oxidoreductases. Redox Biol. 2022;54:102388. doi: 10.1016/j.redox.2022.102388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2022.102388</ArticleId><ArticleId IdType="pmc">PMC9239706</ArticleId><ArticleId IdType="pubmed">35792438</ArticleId></ArticleIdList></Reference><Reference><Citation>Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 variants of concern in the United States&#x2014;challenges and opportunities. JAMA. 2021;325:1037&#x2013;8. doi: 10.1001/jama.2021.2294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.2294</ArticleId><ArticleId IdType="pmc">PMC9009864</ArticleId><ArticleId IdType="pubmed">33595644</ArticleId></ArticleIdList></Reference><Reference><Citation>Telenti A, Hodcroft EB, Robertson DL. The evolution and biology of SARS-CoV-2 variants. Cold Spring Harb Perspect Med. 2022;12:a041390. doi: 10.1101/cshperspect.a041390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a041390</ArticleId><ArticleId IdType="pmc">PMC9159258</ArticleId><ArticleId IdType="pubmed">35444005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp SA, Collier DA, Datir RP, Ferreira I, Gayed S, Jahun A, et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592:277&#x2013;82. doi: 10.1038/s41586-021-03291-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03291-y</ArticleId><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo K, Barrett BS, Morrison JH, Mickens KL, Vladar EK, Hasenkrug KJ, et al. Interferon resistance of emerging SARS-CoV-2 variants. Proc Natl Acad Sci USA. 2022;119:e2203760119. doi: 10.1073/pnas.2203760119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2203760119</ArticleId><ArticleId IdType="pmc">PMC9371743</ArticleId><ArticleId IdType="pubmed">35867811</ArticleId></ArticleIdList></Reference><Reference><Citation>Nchioua R, Schundner A, Klute S, Koepke L, Hirschenberger M, Noettger S, et al. Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1. Life Sci Alliance. 2023;6:e202201745. doi: 10.26508/lsa.202201745.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202201745</ArticleId><ArticleId IdType="pmc">PMC10053418</ArticleId><ArticleId IdType="pubmed">36977594</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill V, Du Plessis L, Peacock TP, Aggarwal D, Colquhoun R, Carabelli AM, et al. The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. Virus Evol. 2022;8:veac080. doi: 10.1093/ve/veac080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veac080</ArticleId><ArticleId IdType="pmc">PMC9752794</ArticleId><ArticleId IdType="pubmed">36533153</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Liu J, Johnson BA, Xia H, Ku Z, Schindewolf C, et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Rep. 2022;39:110829. doi: 10.1016/j.celrep.2022.110829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110829</ArticleId><ArticleId IdType="pmc">PMC9050581</ArticleId><ArticleId IdType="pubmed">35550680</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemeyer D, Stenzel S, Veith T, Schroeder S, Friedmann K, Weege F, et al. SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression. PLoS Biol. 2022;20:e3001871. doi: 10.1371/journal.pbio.3001871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001871</ArticleId><ArticleId IdType="pmc">PMC9710838</ArticleId><ArticleId IdType="pubmed">36383605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lista MJ, Winstone H, Wilson HD, Dyer A, Pickering S, Galao RP, et al. The P681H mutation in the spike glycoprotein of the alpha variant of SARS-CoV-2 escapes IFITM restriction and is necessary for type I interferon resistance. J Virol. 2022;96:e0125022. doi: 10.1128/jvi.01250-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01250-22</ArticleId><ArticleId IdType="pmc">PMC9749455</ArticleId><ArticleId IdType="pubmed">36350154</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol. 2022;7:1161&#x2013;79. doi: 10.1038/s41564-022-01143-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01143-7</ArticleId><ArticleId IdType="pmc">PMC9352574</ArticleId><ArticleId IdType="pubmed">35798890</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock TP, Brown JC, Zhou J, Thakur N, Sukhova K, Newman J, et al. The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein. 2021.12.31.474653. 2022. Preprint at 10.1101/2021.12.31.474653.</Citation></Reference><Reference><Citation>Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603:679&#x2013;86. doi: 10.1038/s41586-022-04411-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04411-y</ArticleId><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar MS, Marwal R, Vs R, Ponnusamy K, Jolly B, Bhoyar RC, et al. Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science. 2021;374:995&#x2013;9. doi: 10.1126/science.abj9932.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj9932</ArticleId><ArticleId IdType="pmc">PMC7612010</ArticleId><ArticleId IdType="pubmed">34648303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira IATM, Kemp SA, Datir R, Saito A, Meng B, Rakshit P, et al. SARS-CoV-2 B.1.617 mutations L452R and E484Q are not synergistic for antibody evasion. J Infect Dis. 2021;224:989&#x2013;94. doi: 10.1093/infdis/jiab368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab368</ArticleId><ArticleId IdType="pmc">PMC8420622</ArticleId><ArticleId IdType="pubmed">34260717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D, Rothenburger T, Ciesek S, Wass MN, Michaelis M, Cinatl J JR. SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment. Cell Discov. 2022;8:42. doi: 10.1038/s41421-022-00408-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-022-00408-z</ArticleId><ArticleId IdType="pmc">PMC9087166</ArticleId><ArticleId IdType="pubmed">35538050</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D, Widera M, Ciesek S, Wass MN, Michaelis M, Cinatl J JR. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates. Cell Res. 2022;32:319&#x2013;21. doi: 10.1038/s41422-022-00619-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00619-9</ArticleId><ArticleId IdType="pmc">PMC8781709</ArticleId><ArticleId IdType="pubmed">35064226</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhaddou M, Reuschl AK, Polacco BJ, Thorne LG, Ummadi MR, Ye C, et al. SARS-CoV-2 variants evolve convergent strategies to remodel the host response. Cell. 2023;186:4597&#x2013;614. doi: 10.1016/j.cell.2023.08.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.08.026</ArticleId><ArticleId IdType="pmc">PMC10604369</ArticleId><ArticleId IdType="pubmed">37738970</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516&#x2013;27. doi: 10.1038/s41586-020-2798-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2798-3</ArticleId><ArticleId IdType="pubmed">32967006</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383:1920&#x2013;31. doi: 10.1056/NEJMoa2022483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022483</ArticleId><ArticleId IdType="pmc">PMC7377258</ArticleId><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. JAMA. 2021;325:1318&#x2013;20. doi: 10.1001/jama.2021.3199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3199</ArticleId><ArticleId IdType="pubmed">33635317</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M, Piancone F, Marventano I, Hernis A, Trabattoni D, Invernizzi M, et al. Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine. Front Immunol. 2022;13:947320. doi: 10.3389/fimmu.2022.947320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.947320</ArticleId><ArticleId IdType="pmc">PMC9443429</ArticleId><ArticleId IdType="pubmed">36072604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cros J, Cagnard N, Woollard K, Patey N, Zhang SY, Senechal B, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity. 2010;33:375&#x2013;86. doi: 10.1016/j.immuni.2010.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.08.012</ArticleId><ArticleId IdType="pmc">PMC3063338</ArticleId><ArticleId IdType="pubmed">20832340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagemann K, Riecken K, Jung JM, Hildebrandt H, Menzel S, Bunders MJ, et al. Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients. Eur J Immunol. 2022;52:1297&#x2013;307. doi: 10.1002/eji.202149470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202149470</ArticleId><ArticleId IdType="pmc">PMC9087393</ArticleId><ArticleId IdType="pubmed">35416291</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, Scott M, Hagan T, Li C, Feng Y, Wimmers F, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021;596:410&#x2013;6. doi: 10.1038/s41586-021-03791-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03791-x</ArticleId><ArticleId IdType="pmc">PMC8761119</ArticleId><ArticleId IdType="pubmed">34252919</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020;27:3209&#x2013;25. doi: 10.1038/s41418-020-00633-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00633-7</ArticleId><ArticleId IdType="pmc">PMC7545020</ArticleId><ArticleId IdType="pubmed">33037393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira IATM, Lee C, Foster WS, Abdullahi A, Dratva LM, Tuong ZK, et al. Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly. Cell Rep. 2023;42:112991. doi: 10.1016/j.celrep.2023.112991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112991</ArticleId><ArticleId IdType="pubmed">37590132</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier DA, Ferreira I, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417&#x2013;22. doi: 10.1038/s41586-021-03739-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03739-1</ArticleId><ArticleId IdType="pmc">PMC8373615</ArticleId><ArticleId IdType="pubmed">34192737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JL, Innocentin S, Silva-Cayetano A, Guillaume SM, Linterman MA. B cells from aged mice do not have intrinsic defects in affinity maturation. 2023.04.24.538044. 2023. Preprint at 10.1101/2023.04.24.538044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10627434</ArticleId><ArticleId IdType="pubmed">37756528</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JL, Fra-Bido SC, Burton AR, Innocentin S, Hill DL, Linterman MA. B cell-intrinsic changes with age do not impact antibody-secreting cell formation but delay B cell participation in the germinal centre reaction. Aging Cell. 2022;21:e13692. doi: 10.1111/acel.13692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13692</ArticleId><ArticleId IdType="pmc">PMC9470890</ArticleId><ArticleId IdType="pubmed">35980826</ArticleId></ArticleIdList></Reference><Reference><Citation>Denton AE, Dooley J, Cinti I, Silva-Cayetano A, Fra-Bido S, Innocentin S, et al. Targeting TLR4 during vaccination boosts MAdCAM-1+ lymphoid stromal cell activation and promotes the aged germinal center response. Sci Immunol. 2022;7:eabk0018. doi: 10.1126/sciimmunol.abk0018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abk0018</ArticleId><ArticleId IdType="pmc">PMC7612953</ArticleId><ArticleId IdType="pubmed">35522725</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205&#x2013;11. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa Duque JS, Wang X, Leung D, Cheng S, Cohen CA, Mu X, et al. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. Nat Commun. 2022;13:3700. doi: 10.1038/s41467-022-31485-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31485-z</ArticleId><ArticleId IdType="pmc">PMC9240007</ArticleId><ArticleId IdType="pubmed">35764637</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. eBioMedicine. 2022;77:103904. doi: 10.1016/j.ebiom.2022.103904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103904</ArticleId><ArticleId IdType="pmc">PMC8893246</ArticleId><ArticleId IdType="pubmed">35248996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe. 2021;2:e423. doi: 10.1016/S2666-5247(21)00177-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00177-4</ArticleId><ArticleId IdType="pmc">PMC8282488</ArticleId><ArticleId IdType="pubmed">34308395</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Shen H, Huang R, Tong X, Wu C. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. Lancet Infect Dis. 2021;21:1071&#x2013;2. doi: 10.1016/S1473-3099(21)00287-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00287-5</ArticleId><ArticleId IdType="pmc">PMC8159188</ArticleId><ArticleId IdType="pubmed">34051887</ArticleId></ArticleIdList></Reference><Reference><Citation>McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau E, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 2022;22:1435&#x2013;43. doi: 10.1016/S1473-3099(22)00345-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00345-0</ArticleId><ArticleId IdType="pmc">PMC9286709</ArticleId><ArticleId IdType="pubmed">35850128</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Lin Y, Li Y, Chen S, Zhou L, Song H, et al. Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine. Cell. 2023;186:4615&#x2013;31.e16. doi: 10.1016/j.cell.2023.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.08.033</ArticleId><ArticleId IdType="pubmed">37769658</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier C, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23:210&#x2013;6. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022;3:100663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224:1839&#x2013;48. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntur VP, Nemkov T, de Boer E, Mohning MP, Baraghoshi D, Cendali FI, et al. Signatures of mitochondrial dysfunction and impaired fatty acid metabolism in plasma of patients with post-acute sequelae of COVID-19 (PASC) Metabolites. 2022;12:1026. doi: 10.3390/metabo12111026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12111026</ArticleId><ArticleId IdType="pmc">PMC9699059</ArticleId><ArticleId IdType="pubmed">36355108</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az-Resendiz KJG, Benitez-Trinidad AB, Covantes-Rosales CE, Toledo-Ibarra GA, Ortiz-Lazareno PC, Gir&#xf3;n-P&#xe9;rez DA, et al. Loss of mitochondrial membrane potential (&#x394;&#x3a8;m) in leucocytes as post-COVID-19 sequelae. J Leukoc Biol. 2022;112:23&#x2013;29. doi: 10.1002/JLB.3MA0322-279RRR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3MA0322-279RRR</ArticleId><ArticleId IdType="pmc">PMC9088601</ArticleId><ArticleId IdType="pubmed">35355308</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG, Mustapic M, Kapogiannis D, Henrich TJ, Lu S, et al. SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19. Ann Neurol. 2022;91:772&#x2013;81. doi: 10.1002/ana.26350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26350</ArticleId><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiner P, Harrer T, Scheibenbogen C, Lamer S, Schlosser A, Naviaux RK, et al. Human herpesvirus-6 reactivation, mitochondrial fragmentation, and the coordination of antiviral and metabolic phenotypes in myalgic encephalomyelitis/chronic fatigue syndrome. ImmunoHorizons. 2020;4:201&#x2013;15. doi: 10.4049/immunohorizons.2000006.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2000006</ArticleId><ArticleId IdType="pubmed">32327453</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubchenko S, Kril I, Nadizhko O, Matsyura O, Chopyak V. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol Int. 2022;42:1523&#x2013;30. doi: 10.1007/s00296-022-05146-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05146-9</ArticleId><ArticleId IdType="pmc">PMC9159383</ArticleId><ArticleId IdType="pubmed">35650445</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023;133:e163669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;95.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Moustaqil M, Ollivier E, Chiu HP, Van Tol S, Rudolffi-Soto P, Stevens C, et al. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species. Emerg Microbes Infect. 2021;10:178&#x2013;95. doi: 10.1080/22221751.2020.1870414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1870414</ArticleId><ArticleId IdType="pmc">PMC7850364</ArticleId><ArticleId IdType="pubmed">33372854</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng K, Zhang HJ, Min YQ, Zhou M, Deng F, Wang HL, et al. SARS-CoV-2 NSP13 interacts with host IRF3, blocking antiviral immune responses. J Med Virol. 2023;95:e28881. doi: 10.1002/jmv.28881.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28881</ArticleId><ArticleId IdType="pubmed">37314155</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung S-Y, Siu KL, Lin H, Chan CP, Yeung ML, Jin DY. SARS-CoV-2 NSP13 helicase suppresses interferon signaling by perturbing JAK1 phosphorylation of STAT1. Cell Biosci. 2022;12:36. doi: 10.1186/s13578-022-00770-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-022-00770-1</ArticleId><ArticleId IdType="pmc">PMC8939493</ArticleId><ArticleId IdType="pubmed">35317858</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>